Literature DB >> 31874070

Comparative Approaches to Drug Pricing.

So-Yeon Kang1, Ge Bai1,2, Michael J DiStefano1, Mariana P Socal1, Farah Yehia1, Gerard F Anderson1,3.   

Abstract

The United States relies primarily on market forces to determine prices for drugs, whereas most other industrialized countries use a variety of approaches to determine drug prices. Branded drug companies have patents and market exclusivity periods in most industrialized countries. During this period, pharmaceutical companies are allowed to set their list price as high as they prefer in the United States owing to the absence of government price control mechanisms that exist in other countries. Insured patients often pay a percentage of the list price, and cost sharing creates some pressure to lower the list price. Pharmacy benefit managers negotiate with drug companies for lower prices by offering the drug company favorable formulary placement and fewer utilization controls. However, these approaches appear to be less effective, compared with other countries' approaches to containing branded drug prices, because prices are substantially higher in the United States. Other industrialized countries employ various forms of rate setting and price regulation, such as external reference pricing, therapeutic valuation, and health technology assessment to determine the appropriate price.

Entities:  

Keywords:  ability to pay; access to pharmaceuticals; drug innovation; drug prices; external reference prices

Mesh:

Year:  2019        PMID: 31874070     DOI: 10.1146/annurev-publhealth-040119-094305

Source DB:  PubMed          Journal:  Annu Rev Public Health        ISSN: 0163-7525            Impact factor:   21.981


  4 in total

1.  Market concentration of new antibiotic sales.

Authors:  Sakib Rahman; Olof Lindahl; Chantal M Morel; Aidan Hollis
Journal:  J Antibiot (Tokyo)       Date:  2021-03-04       Impact factor: 2.649

Review 2.  Value and affordability of CAR T-cell therapy in the United States.

Authors:  Salvatore Fiorenza; David S Ritchie; Scott D Ramsey; Cameron J Turtle; Joshua A Roth
Journal:  Bone Marrow Transplant       Date:  2020-05-30       Impact factor: 5.483

3.  Direct costs of adhering to selected Duchenne muscular dystrophy Care Considerations: Estimates from a midwestern state.

Authors:  Kristin M Conway; Scott D Grosse; Lijing Ouyang; Natalie Street; Paul A Romitti
Journal:  Muscle Nerve       Date:  2022-02-09       Impact factor: 3.852

4.  Drug costs in context: assessing drug costs in cost-of-illness analyses.

Authors:  T Joseph Mattingly; Shannon Weathers
Journal:  Drugs Context       Date:  2022-07-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.